Trending Topic

2 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

We are pleased to present the latest issue of touchREVIEWS in Endocrinology, which offers a timely and thoughtprovoking collection of articles that reflect both the continuity and evolution of diabetes and metabolic disease research. In an era where technology, public health priorities and clinical paradigms are shifting rapidly, this issue highlights the importance of evidence-based […]

Bone Disorders

International Partner

isge-logo2.gif

An Introduction to Bone Disorders

Osteoporosis medications aim to markedly reduce the occurrence of fractures but can have rare and serious adverse effects. The introduction of new drug classes, including an anti-sclerostin monoclonal antibody and a parathyroid hormone-related peptide analogue, into the treatment landscape, offers new options to patients. The potential for cell-based therapies and drugs that target the elimination of senescent cells in the bone microenvironment are currently being investigated.

Browse our gallery of video highlights and short articles from the conference hub, providing the latest expert insights from major conferences and peer-reviewed articles from the journal portfolio.

Our supporting partners do not constitute an endorsement of the content on this page.

Mark CompleteCompleted
BookmarkBookmarked

What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.

58 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchMDT
Prof. Karin Blakemore, Prof. Janet Legare, Prof. Dr. med. Klaus Mohnike, Ms Carly Kutner

A multidisciplinary team and a patient advocate discuss the importance of diagnosis, monitoring, and early treatment in achondroplasia

35 mins
CE/CME accredited
Mark CompleteCompleted
BookmarkBookmarked
touchIN CONVERSATION
Dr Nadia Merchant, Dr Andrew Dauber

Watch experts in paediatric endocrinology discuss the physiology of normal and abnormal bone growth, and the assessment and treatment of achondroplasia.

Mark CompleteCompleted
BookmarkBookmarked
Hiya Boro, Saurav Khatiwada, Sarah Alam

Renal tubular acidosis (RTA) is characterized by the impaired ability of the kidneys to absorb filtered bicarbonate or to excrete titrable acid in urine.1 It manifests as normal anion gap (hyperchloremic) metabolic acidosis. RTA may be of four types: type 1 (...

Mark CompleteCompleted
BookmarkBookmarked

Osteoporosis is a major health issue, affecting around 200 million women worldwide. Although osteoporosis is typically associated with women, it is also diagnosed in men; one in three women over age 50 will experience osteoporotic fractures, as will one in five men ...

Mark CompleteCompleted
BookmarkBookmarked

As the population ages, the need to promote good musculoskeletal health throughout the lifecourse increases. Physical activity and adequate nutrition are known to be beneficial to bone and muscle at all ages; individually the benefits of physical activity and inadequate ...

Mark CompleteCompleted
BookmarkBookmarked

  Disorders related to bone health are commonly seen in clinical practice in India. The most common conditions are vitamin D deficiency-related disorders (rickets, osteomalacia), followed by osteoporosis, hyperparathyroidism, endocrine osteopathies, and impaired bone health associated with systemic diseases.1–3 Vitamin ...

Mark CompleteCompleted
BookmarkBookmarked

  Diabetes mellitus has been associated with decreased bone quality and higher risk of fractures in several studies.1–3 Patients with type 1 diabetes have lower bone mineral density and patients with type 2 diabetes have an increased risk of fracture despite normal ...

Mark CompleteCompleted
BookmarkBookmarked

It is highly appealing to manage osteoporosis and reduce risk of fracture by using drugs that can restore bone microarchitecture and bone strength; such drugs are bone anabolic agents. Teriparatide is the only currently licensed anabolic bone drug and has ...

Load More...
Close Popup